 Alan Palestine
Concepts (670)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uveitis | 68 | 2023 | 115 | 7.830 |
Why?
| | Panuveitis | 4 | 2023 | 6 | 3.350 |
Why?
| | Uveitis, Intermediate | 4 | 2023 | 7 | 2.460 |
Why?
| | Cataract | 6 | 2023 | 185 | 2.380 |
Why?
| | Fluocinolone Acetonide | 3 | 2023 | 16 | 2.360 |
Why?
| | Visual Acuity | 26 | 2023 | 273 | 2.140 |
Why?
| | Eye Infections, Bacterial | 5 | 2020 | 26 | 1.920 |
Why?
| | Retinopathy of Prematurity | 8 | 2020 | 111 | 1.900 |
Why?
| | Endophthalmitis | 6 | 2020 | 25 | 1.870 |
Why?
| | Glucocorticoids | 7 | 2023 | 552 | 1.830 |
Why?
| | Macular Edema | 5 | 2023 | 35 | 1.810 |
Why?
| | Scleritis | 3 | 2022 | 18 | 1.720 |
Why?
| | Corneal Ulcer | 2 | 2022 | 14 | 1.650 |
Why?
| | Vitrectomy | 8 | 2020 | 57 | 1.650 |
Why?
| | Macular Degeneration | 9 | 2023 | 152 | 1.550 |
Why?
| | Arthritis, Juvenile | 2 | 2022 | 42 | 1.350 |
Why?
| | Fluorescein Angiography | 14 | 2023 | 102 | 1.330 |
Why?
| | Vitreous Body | 15 | 2022 | 102 | 1.320 |
Why?
| | Ocular Hypertension | 4 | 2022 | 61 | 1.150 |
Why?
| | Postoperative Complications | 7 | 2021 | 2161 | 1.110 |
Why?
| | Cytomegalovirus Retinitis | 5 | 2022 | 17 | 1.100 |
Why?
| | Cyclosporins | 31 | 1991 | 59 | 1.060 |
Why?
| | Glaucoma | 3 | 2023 | 204 | 0.990 |
Why?
| | Cataract Extraction | 4 | 2023 | 76 | 0.990 |
Why?
| | Drug Costs | 2 | 2016 | 91 | 0.960 |
Why?
| | Tomography, Optical Coherence | 4 | 2021 | 128 | 0.960 |
Why?
| | Intraocular Pressure | 9 | 2022 | 277 | 0.930 |
Why?
| | Retinal Vessels | 6 | 2021 | 51 | 0.930 |
Why?
| | Geographic Atrophy | 5 | 2023 | 49 | 0.900 |
Why?
| | Inflammation | 10 | 2023 | 2499 | 0.890 |
Why?
| | Uveitis, Posterior | 5 | 2019 | 12 | 0.870 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2020 | 519 | 0.870 |
Why?
| | Diabetic Retinopathy | 2 | 2022 | 149 | 0.870 |
Why?
| | Anterior Chamber | 5 | 2021 | 20 | 0.860 |
Why?
| | Antirheumatic Agents | 2 | 2022 | 255 | 0.860 |
Why?
| | Humans | 169 | 2023 | 115587 | 0.850 |
Why?
| | Keratoconjunctivitis Sicca | 1 | 2022 | 4 | 0.850 |
Why?
| | Retinal Detachment | 3 | 2020 | 53 | 0.850 |
Why?
| | Eye Diseases | 10 | 2020 | 76 | 0.840 |
Why?
| | Retinitis | 15 | 1993 | 17 | 0.830 |
Why?
| | Methotrexate | 3 | 2022 | 228 | 0.820 |
Why?
| | Behcet Syndrome | 7 | 2021 | 17 | 0.810 |
Why?
| | Health Care Costs | 2 | 2016 | 384 | 0.800 |
Why?
| | Retinal Diseases | 6 | 2020 | 77 | 0.780 |
Why?
| | Corneal Transplantation | 4 | 2020 | 10 | 0.780 |
Why?
| | Acquired Immunodeficiency Syndrome | 22 | 1996 | 221 | 0.770 |
Why?
| | Retinal Vasculitis | 1 | 2021 | 7 | 0.760 |
Why?
| | Azathioprine | 2 | 2022 | 50 | 0.760 |
Why?
| | Retrospective Studies | 28 | 2022 | 12608 | 0.740 |
Why?
| | Eye Banks | 1 | 2020 | 6 | 0.740 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2020 | 41 | 0.690 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2019 | 66 | 0.670 |
Why?
| | Homosexuality, Male | 1 | 2020 | 170 | 0.670 |
Why?
| | Practice Patterns, Physicians' | 3 | 2016 | 1180 | 0.640 |
Why?
| | Surveys and Questionnaires | 8 | 2022 | 4665 | 0.630 |
Why?
| | International Classification of Diseases | 1 | 2018 | 118 | 0.600 |
Why?
| | Cytomegalovirus | 3 | 2022 | 146 | 0.600 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2019 | 192 | 0.590 |
Why?
| | Sarcoidosis | 9 | 2023 | 134 | 0.580 |
Why?
| | Fetal Membranes, Premature Rupture | 1 | 2017 | 34 | 0.570 |
Why?
| | Adrenal Cortex Hormones | 4 | 2023 | 509 | 0.570 |
Why?
| | Labor, Induced | 1 | 2017 | 32 | 0.570 |
Why?
| | Labor, Obstetric | 1 | 2017 | 53 | 0.560 |
Why?
| | Retinal Drusen | 3 | 2021 | 25 | 0.560 |
Why?
| | Rheumatologists | 1 | 2016 | 12 | 0.560 |
Why?
| | Drug Implants | 5 | 2022 | 71 | 0.550 |
Why?
| | Ophthalmologists | 1 | 2016 | 12 | 0.550 |
Why?
| | Conjunctivitis | 2 | 2015 | 17 | 0.540 |
Why?
| | Adult | 71 | 2022 | 30718 | 0.540 |
Why?
| | Autoimmune Diseases | 20 | 2009 | 395 | 0.540 |
Why?
| | Polychondritis, Relapsing | 1 | 2015 | 2 | 0.530 |
Why?
| | Insurance, Health | 2 | 2016 | 246 | 0.530 |
Why?
| | Ear Auricle | 1 | 2015 | 11 | 0.530 |
Why?
| | Vision Disorders | 2 | 2016 | 130 | 0.520 |
Why?
| | Female | 98 | 2023 | 59913 | 0.510 |
Why?
| | Neonatal Screening | 4 | 2018 | 151 | 0.500 |
Why?
| | Wet Macular Degeneration | 3 | 2020 | 32 | 0.500 |
Why?
| | Surgical Wound Infection | 1 | 2018 | 250 | 0.500 |
Why?
| | Needles | 1 | 2015 | 52 | 0.500 |
Why?
| | Male | 81 | 2023 | 55949 | 0.490 |
Why?
| | Biopsy, Needle | 1 | 2015 | 183 | 0.490 |
Why?
| | Diabetes Mellitus | 2 | 2022 | 906 | 0.490 |
Why?
| | DNA, Viral | 1 | 2016 | 351 | 0.480 |
Why?
| | Aged | 38 | 2023 | 19251 | 0.470 |
Why?
| | Middle Aged | 52 | 2021 | 26999 | 0.460 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 1002 | 0.460 |
Why?
| | Premature Birth | 1 | 2017 | 278 | 0.450 |
Why?
| | Databases, Factual | 1 | 2018 | 1138 | 0.450 |
Why?
| | Complement Activation | 3 | 2022 | 343 | 0.450 |
Why?
| | Follow-Up Studies | 12 | 2021 | 4440 | 0.430 |
Why?
| | Vaccination | 1 | 2021 | 1209 | 0.430 |
Why?
| | Gestational Age | 8 | 2020 | 757 | 0.430 |
Why?
| | Melanoma | 1 | 2019 | 651 | 0.430 |
Why?
| | Bacteria | 2 | 2018 | 729 | 0.430 |
Why?
| | Immunosuppressive Agents | 5 | 2022 | 666 | 0.420 |
Why?
| | Ophthalmology | 3 | 2022 | 77 | 0.420 |
Why?
| | Cytomegalovirus Infections | 12 | 1999 | 182 | 0.420 |
Why?
| | Antiviral Agents | 11 | 2022 | 651 | 0.420 |
Why?
| | Placenta | 1 | 2018 | 624 | 0.410 |
Why?
| | Skin Neoplasms | 2 | 2019 | 761 | 0.410 |
Why?
| | Antineoplastic Agents | 3 | 2020 | 1893 | 0.410 |
Why?
| | Steroids | 2 | 2023 | 147 | 0.400 |
Why?
| | Electronic Health Records | 1 | 2018 | 805 | 0.400 |
Why?
| | Anti-Bacterial Agents | 2 | 2018 | 1484 | 0.380 |
Why?
| | AIDS-Related Opportunistic Infections | 3 | 2022 | 117 | 0.380 |
Why?
| | Macula Lutea | 3 | 2020 | 15 | 0.370 |
Why?
| | Colorado | 9 | 2022 | 4113 | 0.360 |
Why?
| | Ciliary Body | 9 | 2018 | 33 | 0.360 |
Why?
| | Registries | 4 | 2023 | 1770 | 0.360 |
Why?
| | Trabeculectomy | 2 | 2022 | 65 | 0.360 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1405 | 0.350 |
Why?
| | Complement Factor B | 2 | 2022 | 100 | 0.350 |
Why?
| | United States | 11 | 2023 | 12295 | 0.340 |
Why?
| | Ganciclovir | 9 | 2022 | 49 | 0.340 |
Why?
| | Aged, 80 and over | 12 | 2021 | 6417 | 0.330 |
Why?
| | Glaucoma, Open-Angle | 2 | 2022 | 95 | 0.320 |
Why?
| | Aqueous Humor | 4 | 2022 | 31 | 0.320 |
Why?
| | Antigens | 14 | 1990 | 323 | 0.320 |
Why?
| | Complement System Proteins | 3 | 2022 | 288 | 0.320 |
Why?
| | Eye Proteins | 7 | 1990 | 73 | 0.300 |
Why?
| | Conjunctival Diseases | 3 | 2017 | 17 | 0.300 |
Why?
| | Cyclosporine | 2 | 2022 | 169 | 0.300 |
Why?
| | Retina | 18 | 1993 | 267 | 0.290 |
Why?
| | Adolescent | 27 | 2022 | 17889 | 0.290 |
Why?
| | Birth Weight | 4 | 2020 | 438 | 0.290 |
Why?
| | Uveitis, Anterior | 4 | 2018 | 11 | 0.280 |
Why?
| | Corneal Diseases | 5 | 2017 | 34 | 0.280 |
Why?
| | Child | 21 | 2022 | 18488 | 0.270 |
Why?
| | Incidence | 6 | 2021 | 2335 | 0.270 |
Why?
| | Opportunistic Infections | 4 | 1991 | 44 | 0.260 |
Why?
| | Adalimumab | 2 | 2022 | 44 | 0.260 |
Why?
| | Biological Factors | 2 | 2022 | 37 | 0.250 |
Why?
| | Fundus Oculi | 7 | 2021 | 40 | 0.250 |
Why?
| | Risk Factors | 10 | 2020 | 8697 | 0.250 |
Why?
| | Chemokine CCL5 | 2 | 2023 | 46 | 0.250 |
Why?
| | Bromocriptine | 4 | 1990 | 27 | 0.250 |
Why?
| | Time Factors | 12 | 2021 | 6165 | 0.250 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 4435 | 0.250 |
Why?
| | Infant | 9 | 2022 | 7979 | 0.240 |
Why?
| | Laser Therapy | 5 | 2021 | 99 | 0.240 |
Why?
| | Specialization | 2 | 2016 | 117 | 0.240 |
Why?
| | Infant, Premature | 2 | 2019 | 477 | 0.240 |
Why?
| | Child, Preschool | 9 | 2022 | 9133 | 0.240 |
Why?
| | Retinal Vein Occlusion | 1 | 2004 | 13 | 0.230 |
Why?
| | Cohort Studies | 7 | 2020 | 4944 | 0.230 |
Why?
| | Quality of Life | 3 | 2023 | 2385 | 0.230 |
Why?
| | Mycophenolic Acid | 2 | 2022 | 81 | 0.220 |
Why?
| | Fluoresceins | 5 | 1989 | 46 | 0.220 |
Why?
| | Young Adult | 6 | 2021 | 10470 | 0.220 |
Why?
| | Choroid | 11 | 2021 | 47 | 0.220 |
Why?
| | Algorithms | 4 | 2018 | 1490 | 0.220 |
Why?
| | Phacoemulsification | 3 | 2019 | 107 | 0.220 |
Why?
| | Infant, Very Low Birth Weight | 3 | 2018 | 65 | 0.220 |
Why?
| | Anti-Inflammatory Agents | 3 | 2022 | 448 | 0.210 |
Why?
| | Etanercept | 1 | 2022 | 51 | 0.210 |
Why?
| | Histocompatibility Antigens Class II | 9 | 1994 | 353 | 0.210 |
Why?
| | Foscarnet | 4 | 1996 | 18 | 0.210 |
Why?
| | Eye Neoplasms | 3 | 2017 | 15 | 0.200 |
Why?
| | Reference Standards | 2 | 2022 | 161 | 0.200 |
Why?
| | Antibodies, Monoclonal | 12 | 2020 | 1265 | 0.200 |
Why?
| | Tacrolimus | 1 | 2022 | 143 | 0.200 |
Why?
| | Albumins | 1 | 2022 | 91 | 0.200 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 7 | 0.190 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 10 | 0.190 |
Why?
| | Eye Infections, Viral | 2 | 1991 | 7 | 0.190 |
Why?
| | Capsule Opacification | 1 | 2021 | 20 | 0.190 |
Why?
| | Graft Rejection | 3 | 2021 | 533 | 0.190 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 22 | 0.190 |
Why?
| | Rats, Inbred Lew | 18 | 1994 | 93 | 0.190 |
Why?
| | Sensitivity and Specificity | 4 | 2018 | 1718 | 0.190 |
Why?
| | National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.190 |
Why?
| | T-Lymphocytes, Helper-Inducer | 8 | 1994 | 129 | 0.190 |
Why?
| | Laser Coagulation | 2 | 2018 | 54 | 0.190 |
Why?
| | Retinal Pigment Epithelium | 1 | 2021 | 58 | 0.180 |
Why?
| | Anemia, Sickle Cell | 1 | 2004 | 217 | 0.180 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2020 | 16 | 0.180 |
Why?
| | Treatment Outcome | 9 | 2022 | 9159 | 0.180 |
Why?
| | Multiple Sclerosis | 3 | 2023 | 380 | 0.180 |
Why?
| | Infant, Newborn | 7 | 2020 | 5077 | 0.180 |
Why?
| | Administration, Topical | 4 | 2016 | 137 | 0.180 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 20 | 0.170 |
Why?
| | Scleral Buckling | 1 | 2019 | 18 | 0.170 |
Why?
| | Endotoxins | 3 | 1991 | 207 | 0.170 |
Why?
| | Diagnostic Techniques, Ophthalmological | 2 | 2018 | 36 | 0.170 |
Why?
| | Transplantation, Autologous | 1 | 2020 | 173 | 0.170 |
Why?
| | Canada | 1 | 2020 | 335 | 0.170 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 33 | 0.170 |
Why?
| | Complement C3a | 1 | 2019 | 33 | 0.170 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2022 | 1137 | 0.170 |
Why?
| | Pyrimidinones | 1 | 2019 | 88 | 0.160 |
Why?
| | Acyclovir | 5 | 2001 | 100 | 0.160 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 183 | 0.160 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 116 | 0.160 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 44 | 0.160 |
Why?
| | Decision Making | 2 | 2016 | 791 | 0.160 |
Why?
| | Organ Transplantation | 1 | 2021 | 161 | 0.160 |
Why?
| | Computer Systems | 1 | 2018 | 46 | 0.160 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2018 | 22 | 0.160 |
Why?
| | Viral Load | 2 | 2016 | 405 | 0.160 |
Why?
| | Organophosphonates | 1 | 1998 | 91 | 0.150 |
Why?
| | Biological Products | 1 | 2021 | 172 | 0.150 |
Why?
| | Intravitreal Injections | 1 | 2018 | 46 | 0.150 |
Why?
| | Disease-Free Survival | 1 | 2019 | 621 | 0.150 |
Why?
| | Metformin | 1 | 2021 | 278 | 0.150 |
Why?
| | Risk | 4 | 2018 | 819 | 0.150 |
Why?
| | Reoperation | 1 | 2020 | 525 | 0.150 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 176 | 0.150 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2023 | 1216 | 0.150 |
Why?
| | Farber Lipogranulomatosis | 1 | 2017 | 4 | 0.150 |
Why?
| | Synovitis | 1 | 2017 | 24 | 0.140 |
Why?
| | Amnion | 1 | 2017 | 24 | 0.140 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2017 | 34 | 0.140 |
Why?
| | Parity | 1 | 2017 | 99 | 0.140 |
Why?
| | Burnout, Professional | 1 | 2022 | 322 | 0.140 |
Why?
| | Arrestin | 13 | 1990 | 13 | 0.140 |
Why?
| | Cicatrix | 1 | 2017 | 50 | 0.140 |
Why?
| | Ophthalmoscopy | 1 | 2016 | 30 | 0.140 |
Why?
| | Medical Informatics | 1 | 2017 | 93 | 0.140 |
Why?
| | Infant, Low Birth Weight | 1 | 2017 | 125 | 0.140 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 1000 | 0.140 |
Why?
| | Terminology as Topic | 1 | 2017 | 186 | 0.140 |
Why?
| | Herpes Zoster | 2 | 2009 | 333 | 0.140 |
Why?
| | T-Lymphocytes | 12 | 2022 | 1756 | 0.140 |
Why?
| | Arthritis | 1 | 2017 | 111 | 0.130 |
Why?
| | Lymphocytes | 9 | 1991 | 344 | 0.130 |
Why?
| | Transplantation, Homologous | 2 | 2016 | 397 | 0.130 |
Why?
| | Weight Gain | 2 | 2016 | 453 | 0.130 |
Why?
| | Pregnancy | 2 | 2018 | 5548 | 0.130 |
Why?
| | Recovery of Function | 1 | 2019 | 577 | 0.130 |
Why?
| | Disease Management | 1 | 2019 | 563 | 0.130 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2017 | 154 | 0.130 |
Why?
| | Endoscopy | 1 | 2018 | 247 | 0.130 |
Why?
| | Microbiological Techniques | 1 | 2015 | 29 | 0.130 |
Why?
| | Colony Count, Microbial | 1 | 2015 | 112 | 0.130 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 281 | 0.120 |
Why?
| | Hematologic Neoplasms | 1 | 2016 | 136 | 0.120 |
Why?
| | Rheumatology | 1 | 2016 | 89 | 0.120 |
Why?
| | Rats | 24 | 1994 | 5034 | 0.120 |
Why?
| | Phosphonoacetic Acid | 2 | 1991 | 10 | 0.120 |
Why?
| | Lymphocyte Activation | 8 | 1990 | 1057 | 0.120 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2019 | 330 | 0.120 |
Why?
| | Prospective Studies | 6 | 2020 | 6264 | 0.120 |
Why?
| | Health Care Surveys | 1 | 2016 | 538 | 0.120 |
Why?
| | Reproducibility of Results | 2 | 2018 | 2800 | 0.120 |
Why?
| | Chorioretinitis | 2 | 1992 | 2 | 0.120 |
Why?
| | Toxoplasmosis, Ocular | 2 | 1994 | 2 | 0.120 |
Why?
| | Physicians | 1 | 2022 | 776 | 0.120 |
Why?
| | Fetus | 1 | 2018 | 702 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 273 | 0.110 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 790 | 0.110 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 1998 | 965 | 0.110 |
Why?
| | Lymphoma, B-Cell | 2 | 1993 | 86 | 0.110 |
Why?
| | Kidney Diseases | 6 | 1989 | 354 | 0.110 |
Why?
| | HIV-1 | 1 | 1998 | 771 | 0.110 |
Why?
| | Research Design | 1 | 2019 | 946 | 0.110 |
Why?
| | Creatinine | 7 | 1992 | 430 | 0.110 |
Why?
| | Health Surveys | 1 | 2014 | 446 | 0.110 |
Why?
| | Patient Selection | 1 | 2016 | 654 | 0.110 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 1992 | 97 | 0.110 |
Why?
| | Risk Assessment | 2 | 2019 | 2987 | 0.100 |
Why?
| | Iris | 3 | 1991 | 19 | 0.100 |
Why?
| | HLA Antigens | 7 | 1991 | 223 | 0.100 |
Why?
| | Mothers | 1 | 2018 | 666 | 0.100 |
Why?
| | Pars Planitis | 1 | 1992 | 1 | 0.100 |
Why?
| | Biomarkers | 5 | 2023 | 3466 | 0.100 |
Why?
| | Retinal Necrosis Syndrome, Acute | 1 | 1991 | 9 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1361 | 0.100 |
Why?
| | Patient Care Team | 1 | 2016 | 521 | 0.100 |
Why?
| | Injections, Intravenous | 7 | 1999 | 204 | 0.100 |
Why?
| | Capillary Permeability | 2 | 1991 | 138 | 0.090 |
Why?
| | Clinical Competence | 1 | 2018 | 912 | 0.090 |
Why?
| | HIV | 4 | 2020 | 209 | 0.090 |
Why?
| | Bacterial Infections | 3 | 1989 | 222 | 0.090 |
Why?
| | Toxoplasma | 2 | 1994 | 33 | 0.090 |
Why?
| | Cytophagaceae | 1 | 1990 | 1 | 0.090 |
Why?
| | Capnocytophaga | 1 | 1990 | 2 | 0.090 |
Why?
| | Antigens, Surface | 3 | 1989 | 151 | 0.090 |
Why?
| | Granuloma | 4 | 2023 | 85 | 0.090 |
Why?
| | Urine | 1 | 1989 | 56 | 0.080 |
Why?
| | Antigens, Protozoan | 1 | 1989 | 19 | 0.080 |
Why?
| | Animals | 34 | 2021 | 32102 | 0.080 |
Why?
| | Sebaceous Gland Neoplasms | 1 | 1989 | 2 | 0.080 |
Why?
| | Eyelid Neoplasms | 1 | 1989 | 8 | 0.080 |
Why?
| | Blood Chemical Analysis | 1 | 1989 | 90 | 0.080 |
Why?
| | Odds Ratio | 4 | 2019 | 962 | 0.080 |
Why?
| | Drug Therapy, Combination | 5 | 1998 | 962 | 0.080 |
Why?
| | Tonometry, Ocular | 2 | 2019 | 83 | 0.080 |
Why?
| | Eye | 7 | 1988 | 101 | 0.080 |
Why?
| | Postoperative Period | 2 | 2019 | 292 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 8 | 2019 | 795 | 0.070 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 1987 | 14 | 0.070 |
Why?
| | Antibody Formation | 3 | 1985 | 273 | 0.070 |
Why?
| | Escherichia coli | 1 | 1991 | 730 | 0.070 |
Why?
| | Autoantibodies | 6 | 1992 | 1360 | 0.070 |
Why?
| | Dextrans | 1 | 1987 | 74 | 0.070 |
Why?
| | Fanconi Syndrome | 1 | 1986 | 2 | 0.070 |
Why?
| | Cell Movement | 2 | 1988 | 867 | 0.070 |
Why?
| | Prednisolone | 2 | 2020 | 77 | 0.070 |
Why?
| | Lymphocyte Transfusion | 1 | 1986 | 19 | 0.070 |
Why?
| | Immunoenzyme Techniques | 8 | 1991 | 193 | 0.070 |
Why?
| | Phenotype | 4 | 2022 | 2829 | 0.070 |
Why?
| | Infliximab | 2 | 2021 | 94 | 0.070 |
Why?
| | Interferometry | 1 | 1985 | 4 | 0.070 |
Why?
| | Lasers | 2 | 1985 | 121 | 0.070 |
Why?
| | Lenses, Intraocular | 2 | 2021 | 42 | 0.060 |
Why?
| | Panophthalmitis | 1 | 1985 | 2 | 0.060 |
Why?
| | Uveomeningoencephalitic Syndrome | 3 | 1990 | 6 | 0.060 |
Why?
| | Protein S Deficiency | 1 | 2004 | 6 | 0.060 |
Why?
| | Choroiditis | 4 | 1991 | 6 | 0.060 |
Why?
| | Biopsy | 5 | 1993 | 1056 | 0.060 |
Why?
| | Myopia | 1 | 1984 | 37 | 0.060 |
Why?
| | Microscopy, Electron | 8 | 1988 | 409 | 0.060 |
Why?
| | Tears | 4 | 1987 | 14 | 0.060 |
Why?
| | Phagocyte Bactericidal Dysfunction | 1 | 1983 | 12 | 0.060 |
Why?
| | Tretinoin | 1 | 1984 | 124 | 0.060 |
Why?
| | Retinal Artery | 2 | 1987 | 15 | 0.060 |
Why?
| | Ophthalmia, Sympathetic | 3 | 1990 | 3 | 0.060 |
Why?
| | Keratoplasty, Penetrating | 2 | 1994 | 4 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2020 | 3022 | 0.050 |
Why?
| | Immunologic Memory | 1 | 1985 | 314 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 209 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 1989 | 799 | 0.050 |
Why?
| | Immunohistochemistry | 6 | 1993 | 1642 | 0.050 |
Why?
| | Deltaretrovirus | 3 | 1986 | 12 | 0.050 |
Why?
| | Aneurysm | 1 | 1982 | 29 | 0.050 |
Why?
| | Cavernous Sinus | 1 | 1981 | 14 | 0.050 |
Why?
| | 2-Aminopurine | 1 | 2001 | 10 | 0.050 |
Why?
| | Herpes Zoster Ophthalmicus | 1 | 2001 | 5 | 0.050 |
Why?
| | Infusions, Intravenous | 2 | 2020 | 374 | 0.050 |
Why?
| | Arteriovenous Fistula | 1 | 1981 | 29 | 0.050 |
Why?
| | Fibrinogen | 1 | 2022 | 160 | 0.050 |
Why?
| | Transplantation Tolerance | 1 | 2021 | 31 | 0.050 |
Why?
| | Abatacept | 1 | 2021 | 40 | 0.050 |
Why?
| | Pigment Epithelium of Eye | 4 | 1990 | 34 | 0.050 |
Why?
| | Disease Models, Animal | 3 | 1991 | 3580 | 0.050 |
Why?
| | Tertiary Healthcare | 1 | 2020 | 29 | 0.050 |
Why?
| | Kidney | 3 | 1989 | 1207 | 0.050 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 50 | 0.050 |
Why?
| | Cyclopentolate | 1 | 2020 | 3 | 0.050 |
Why?
| | Microscopy, Acoustic | 1 | 2020 | 8 | 0.050 |
Why?
| | Gonioscopy | 1 | 2020 | 6 | 0.050 |
Why?
| | Administration, Ophthalmic | 1 | 2020 | 14 | 0.050 |
Why?
| | Muscarinic Antagonists | 1 | 2020 | 27 | 0.040 |
Why?
| | Amyloidosis | 1 | 2020 | 36 | 0.040 |
Why?
| | Carotid Arteries | 1 | 1981 | 183 | 0.040 |
Why?
| | Epithelium | 6 | 1991 | 297 | 0.040 |
Why?
| | Immunologic Factors | 1 | 2022 | 220 | 0.040 |
Why?
| | Hypertension | 5 | 1991 | 1064 | 0.040 |
Why?
| | Anticoagulants | 1 | 2004 | 549 | 0.040 |
Why?
| | Protective Factors | 1 | 2019 | 87 | 0.040 |
Why?
| | Drug Combinations | 1 | 2020 | 289 | 0.040 |
Why?
| | Immunization, Passive | 3 | 1988 | 80 | 0.040 |
Why?
| | Cornea | 4 | 1989 | 107 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2021 | 364 | 0.040 |
Why?
| | Sarcoma, Kaposi | 4 | 1999 | 69 | 0.040 |
Why?
| | Cytosine | 1 | 1998 | 44 | 0.040 |
Why?
| | Trabecular Meshwork | 1 | 2019 | 77 | 0.040 |
Why?
| | CD4 Lymphocyte Count | 1 | 1998 | 257 | 0.040 |
Why?
| | Prolactin | 2 | 1988 | 95 | 0.040 |
Why?
| | Logistic Models | 2 | 2019 | 1856 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2020 | 414 | 0.040 |
Why?
| | Organophosphorus Compounds | 1 | 1998 | 72 | 0.040 |
Why?
| | Conjunctiva | 3 | 1989 | 51 | 0.040 |
Why?
| | Retinol-Binding Proteins | 2 | 1988 | 13 | 0.040 |
Why?
| | Fluorometholone | 1 | 2017 | 4 | 0.040 |
Why?
| | Group Processes | 1 | 2017 | 53 | 0.040 |
Why?
| | Administration, Oral | 3 | 1999 | 734 | 0.040 |
Why?
| | Drug Evaluation | 2 | 1988 | 79 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2022 | 641 | 0.040 |
Why?
| | North America | 1 | 2018 | 261 | 0.040 |
Why?
| | Nod2 Signaling Adaptor Protein | 1 | 2017 | 30 | 0.040 |
Why?
| | Chemotaxis, Leukocyte | 2 | 1987 | 130 | 0.040 |
Why?
| | Interferon-gamma | 2 | 1991 | 726 | 0.040 |
Why?
| | Observer Variation | 1 | 2017 | 297 | 0.040 |
Why?
| | HLA-DR Antigens | 5 | 1991 | 221 | 0.030 |
Why?
| | Properdin | 1 | 1976 | 8 | 0.030 |
Why?
| | Cattle | 5 | 1991 | 935 | 0.030 |
Why?
| | ROC Curve | 1 | 2018 | 451 | 0.030 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2016 | 15 | 0.030 |
Why?
| | Rats, Inbred Strains | 5 | 1987 | 376 | 0.030 |
Why?
| | Plasma Cells | 2 | 1987 | 57 | 0.030 |
Why?
| | Drug Resistance, Microbial | 1 | 1996 | 66 | 0.030 |
Why?
| | Proteins | 2 | 2020 | 920 | 0.030 |
Why?
| | Chronic Disease | 4 | 1990 | 1598 | 0.030 |
Why?
| | Magnesium | 2 | 1986 | 145 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 526 | 0.030 |
Why?
| | Syndrome | 2 | 1987 | 339 | 0.030 |
Why?
| | HIV Infections | 1 | 2009 | 2473 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1440 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 4 | 1988 | 1870 | 0.030 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2017 | 179 | 0.030 |
Why?
| | Glycoproteins | 1 | 1976 | 309 | 0.030 |
Why?
| | Proteomics | 1 | 2020 | 859 | 0.030 |
Why?
| | Recurrence | 2 | 1988 | 952 | 0.030 |
Why?
| | Diagnosis, Differential | 2 | 1988 | 1357 | 0.030 |
Why?
| | Blood Proteins | 2 | 1989 | 238 | 0.030 |
Why?
| | Conjunctival Neoplasms | 2 | 1984 | 7 | 0.030 |
Why?
| | Retinal Hemorrhage | 2 | 1986 | 18 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2021 | 1008 | 0.030 |
Why?
| | Granulomatous Disease, Chronic | 2 | 1983 | 60 | 0.030 |
Why?
| | Models, Biological | 2 | 2016 | 1646 | 0.030 |
Why?
| | T-Lymphocytes, Regulatory | 7 | 1994 | 342 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 4 | 1989 | 398 | 0.030 |
Why?
| | Antibodies, Antinuclear | 2 | 1992 | 60 | 0.030 |
Why?
| | Immunity, Cellular | 2 | 1985 | 262 | 0.030 |
Why?
| | Immunization | 2 | 1985 | 401 | 0.030 |
Why?
| | Dinoprostone | 2 | 1990 | 186 | 0.030 |
Why?
| | Cells, Cultured | 5 | 1991 | 3914 | 0.030 |
Why?
| | Eye Infections | 1 | 1992 | 2 | 0.030 |
Why?
| | Models, Statistical | 1 | 2016 | 606 | 0.030 |
Why?
| | Cell Line | 5 | 1991 | 2651 | 0.030 |
Why?
| | Sepsis | 2 | 1984 | 515 | 0.020 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 2 | 1989 | 85 | 0.020 |
Why?
| | Epitopes | 3 | 1990 | 438 | 0.020 |
Why?
| | Kinetics | 2 | 1988 | 1569 | 0.020 |
Why?
| | Propionibacterium acnes | 1 | 1991 | 8 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2578 | 0.020 |
Why?
| | Indomethacin | 2 | 1990 | 75 | 0.020 |
Why?
| | Transforming Growth Factor beta | 2 | 1991 | 446 | 0.020 |
Why?
| | Dogs | 2 | 1990 | 341 | 0.020 |
Why?
| | B-Lymphocytes | 2 | 1987 | 773 | 0.020 |
Why?
| | Biological Transport, Active | 1 | 1991 | 71 | 0.020 |
Why?
| | Immunoglobulin lambda-Chains | 1 | 1990 | 6 | 0.020 |
Why?
| | Microcirculation | 1 | 1991 | 138 | 0.020 |
Why?
| | Random Allocation | 2 | 1988 | 337 | 0.020 |
Why?
| | Coronary Circulation | 1 | 1991 | 128 | 0.020 |
Why?
| | Protein Binding | 2 | 1989 | 1917 | 0.020 |
Why?
| | Cefazolin | 1 | 1990 | 18 | 0.020 |
Why?
| | Endothelium, Corneal | 1 | 1990 | 15 | 0.020 |
Why?
| | Recombinant Proteins | 2 | 1991 | 1243 | 0.020 |
Why?
| | Flow Cytometry | 2 | 1992 | 1083 | 0.020 |
Why?
| | Fluorescein | 1 | 1989 | 27 | 0.020 |
Why?
| | Keratitis | 2 | 1994 | 11 | 0.020 |
Why?
| | Kidney Function Tests | 2 | 1989 | 141 | 0.020 |
Why?
| | Diagnostic Errors | 1 | 1990 | 151 | 0.020 |
Why?
| | Osmolar Concentration | 1 | 1989 | 178 | 0.020 |
Why?
| | Retroviridae Proteins | 1 | 1989 | 11 | 0.020 |
Why?
| | Hemocyanins | 2 | 1988 | 57 | 0.020 |
Why?
| | Antimetabolites | 1 | 1989 | 21 | 0.020 |
Why?
| | Alkylating Agents | 1 | 1989 | 27 | 0.020 |
Why?
| | Heptanoates | 1 | 1988 | 2 | 0.020 |
Why?
| | Drug Eruptions | 1 | 1989 | 26 | 0.020 |
Why?
| | Interferon Type I | 1 | 1990 | 129 | 0.020 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1989 | 27 | 0.020 |
Why?
| | Candidiasis | 1 | 1989 | 58 | 0.020 |
Why?
| | Suramin | 1 | 1988 | 6 | 0.020 |
Why?
| | Lung Diseases | 2 | 1986 | 710 | 0.020 |
Why?
| | Toxoplasmosis | 1 | 1989 | 31 | 0.020 |
Why?
| | HIV Envelope Protein gp120 | 1 | 1989 | 56 | 0.020 |
Why?
| | Receptors, Virus | 1 | 1989 | 75 | 0.020 |
Why?
| | Lens, Crystalline | 1 | 1990 | 96 | 0.020 |
Why?
| | Heptanoic Acids | 1 | 1988 | 60 | 0.020 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 1989 | 82 | 0.020 |
Why?
| | Dexamethasone | 2 | 1987 | 316 | 0.020 |
Why?
| | Corneal Injuries | 1 | 1989 | 34 | 0.020 |
Why?
| | Mycobacterium Infections | 1 | 1989 | 61 | 0.020 |
Why?
| | Placebos | 1 | 1988 | 198 | 0.020 |
Why?
| | Injections | 1 | 1989 | 161 | 0.020 |
Why?
| | Central Nervous System Diseases | 1 | 1989 | 61 | 0.020 |
Why?
| | Antigen-Antibody Complex | 2 | 1985 | 88 | 0.020 |
Why?
| | HIV Seropositivity | 1 | 1989 | 110 | 0.020 |
Why?
| | Sugar Alcohol Dehydrogenases | 1 | 1987 | 2 | 0.020 |
Why?
| | Imidazolidines | 1 | 1987 | 8 | 0.020 |
Why?
| | Elapid Venoms | 1 | 1987 | 15 | 0.020 |
Why?
| | Galactosemias | 1 | 1987 | 8 | 0.020 |
Why?
| | Colchicine | 1 | 1987 | 24 | 0.020 |
Why?
| | Blood-Retinal Barrier | 1 | 1987 | 13 | 0.020 |
Why?
| | Aldehyde Reductase | 1 | 1987 | 24 | 0.020 |
Why?
| | Community Health Services | 1 | 2009 | 212 | 0.020 |
Why?
| | Specific Gravity | 1 | 1987 | 11 | 0.020 |
Why?
| | Receptors, Interleukin-2 | 1 | 1987 | 65 | 0.020 |
Why?
| | Prednisone | 2 | 1986 | 232 | 0.020 |
Why?
| | Antigens, Differentiation | 1 | 1987 | 79 | 0.020 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 1987 | 6 | 0.020 |
Why?
| | Herpesviridae Infections | 1 | 1989 | 138 | 0.020 |
Why?
| | Pituitary-Adrenal System | 1 | 1989 | 162 | 0.020 |
Why?
| | Drug Interactions | 1 | 1989 | 347 | 0.020 |
Why?
| | Onchocerciasis | 1 | 1987 | 7 | 0.020 |
Why?
| | Down-Regulation | 1 | 1990 | 601 | 0.020 |
Why?
| | Heart Rate | 1 | 1991 | 701 | 0.020 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 1989 | 197 | 0.020 |
Why?
| | Papilledema | 1 | 1987 | 38 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 1990 | 501 | 0.020 |
Why?
| | Organ Specificity | 1 | 1987 | 273 | 0.020 |
Why?
| | Molecular Weight | 1 | 1987 | 329 | 0.020 |
Why?
| | Macaca mulatta | 1 | 1987 | 132 | 0.020 |
Why?
| | Sclera | 1 | 1987 | 35 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 1990 | 826 | 0.020 |
Why?
| | Mutation | 1 | 2017 | 3364 | 0.020 |
Why?
| | Dihydroergotoxine | 1 | 1986 | 1 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 1987 | 203 | 0.020 |
Why?
| | Wound Healing | 1 | 1989 | 257 | 0.020 |
Why?
| | Imidazoles | 1 | 1987 | 217 | 0.020 |
Why?
| | Indium | 1 | 1986 | 10 | 0.020 |
Why?
| | Peritoneal Cavity | 1 | 1986 | 23 | 0.020 |
Why?
| | Radioisotopes | 1 | 1986 | 34 | 0.020 |
Why?
| | Muramidase | 1 | 1986 | 73 | 0.020 |
Why?
| | Immune Tolerance | 1 | 1988 | 332 | 0.020 |
Why?
| | Prognosis | 2 | 1985 | 3339 | 0.020 |
Why?
| | Reference Values | 4 | 1989 | 744 | 0.020 |
Why?
| | Serum Albumin | 1 | 1986 | 135 | 0.020 |
Why?
| | Double-Blind Method | 3 | 2001 | 1660 | 0.020 |
Why?
| | Osteoporosis | 1 | 1989 | 227 | 0.020 |
Why?
| | Peptide Fragments | 1 | 1990 | 675 | 0.020 |
Why?
| | Acute Disease | 2 | 1987 | 914 | 0.020 |
Why?
| | Connective Tissue | 1 | 1985 | 36 | 0.020 |
Why?
| | Vascular Diseases | 1 | 1988 | 230 | 0.020 |
Why?
| | Rabbits | 1 | 1986 | 752 | 0.020 |
Why?
| | Pigmentation Disorders | 1 | 1985 | 7 | 0.020 |
Why?
| | Tetanus Toxoid | 1 | 1985 | 37 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 1992 | 2416 | 0.020 |
Why?
| | Salmonella typhimurium | 1 | 1986 | 161 | 0.020 |
Why?
| | Fibrosis | 1 | 1987 | 457 | 0.020 |
Why?
| | Retinitis Pigmentosa | 1 | 1984 | 16 | 0.020 |
Why?
| | Potassium | 1 | 1985 | 128 | 0.020 |
Why?
| | Pemphigoid, Benign Mucous Membrane | 1 | 1984 | 2 | 0.020 |
Why?
| | Lymphadenitis | 1 | 1984 | 4 | 0.020 |
Why?
| | Antibodies | 1 | 1987 | 374 | 0.020 |
Why?
| | Kidney Glomerulus | 1 | 1985 | 102 | 0.020 |
Why?
| | Tissue Distribution | 1 | 1985 | 324 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2009 | 646 | 0.020 |
Why?
| | Blood Sedimentation | 1 | 1984 | 34 | 0.020 |
Why?
| | Chlorides | 1 | 1985 | 130 | 0.020 |
Why?
| | Kidney Tubules, Proximal | 1 | 1985 | 113 | 0.020 |
Why?
| | Isotretinoin | 1 | 1984 | 22 | 0.010 |
Why?
| | Oculomotor Muscles | 1 | 1984 | 40 | 0.010 |
Why?
| | Peptides | 1 | 1990 | 864 | 0.010 |
Why?
| | Acne Vulgaris | 1 | 1984 | 20 | 0.010 |
Why?
| | Complement C3 | 1 | 1985 | 190 | 0.010 |
Why?
| | Uveal Diseases | 1 | 1983 | 5 | 0.010 |
Why?
| | Optic Neuritis | 1 | 1984 | 37 | 0.010 |
Why?
| | Carbon Dioxide | 1 | 1985 | 211 | 0.010 |
Why?
| | Kidney Failure, Chronic | 1 | 1989 | 490 | 0.010 |
Why?
| | Chediak-Higashi Syndrome | 1 | 1983 | 7 | 0.010 |
Why?
| | Uric Acid | 1 | 1984 | 150 | 0.010 |
Why?
| | Anemia | 1 | 1984 | 144 | 0.010 |
Why?
| | Rats, Inbred BN | 2 | 1994 | 53 | 0.010 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 1984 | 126 | 0.010 |
Why?
| | Liver Diseases | 1 | 1986 | 263 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1986 | 1127 | 0.010 |
Why?
| | Liver | 1 | 1990 | 1690 | 0.010 |
Why?
| | Fluorometry | 1 | 1981 | 19 | 0.010 |
Why?
| | Immunochemistry | 3 | 1986 | 11 | 0.010 |
Why?
| | Melanosis | 1 | 1981 | 13 | 0.010 |
Why?
| | Computers | 1 | 1981 | 60 | 0.010 |
Why?
| | Histocytochemistry | 3 | 1986 | 78 | 0.010 |
Why?
| | Eyelid Diseases | 1 | 1981 | 21 | 0.010 |
Why?
| | Edema | 1 | 1982 | 119 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 1985 | 781 | 0.010 |
Why?
| | Calcium | 1 | 1986 | 1103 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2001 | 309 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 1994 | 156 | 0.010 |
Why?
| | HLA-DQ Antigens | 2 | 1991 | 177 | 0.010 |
Why?
| | Protease Inhibitors | 1 | 1999 | 101 | 0.010 |
Why?
| | Permeability | 2 | 1987 | 150 | 0.010 |
Why?
| | Arthus Reaction | 2 | 1987 | 9 | 0.010 |
Why?
| | Sucrose | 2 | 1987 | 91 | 0.010 |
Why?
| | Photoreceptor Cells | 2 | 1987 | 12 | 0.010 |
Why?
| | Macrophages | 2 | 1994 | 1284 | 0.010 |
Why?
| | Survival Analysis | 1 | 1999 | 1219 | 0.010 |
Why?
| | Immunologic Techniques | 2 | 1986 | 39 | 0.010 |
Why?
| | Tissue Donors | 2 | 1989 | 331 | 0.010 |
Why?
| | Transplantation, Isogeneic | 1 | 1994 | 17 | 0.010 |
Why?
| | Blotting, Southern | 1 | 1994 | 66 | 0.010 |
Why?
| | DNA, Protozoan | 1 | 1994 | 26 | 0.010 |
Why?
| | Shock, Septic | 1 | 1976 | 185 | 0.010 |
Why?
| | Eye Enucleation | 1 | 1993 | 12 | 0.010 |
Why?
| | Viral Proteins | 2 | 1985 | 286 | 0.010 |
Why?
| | Mice | 2 | 1986 | 15052 | 0.010 |
Why?
| | Didanosine | 1 | 1993 | 13 | 0.010 |
Why?
| | Zidovudine | 1 | 1993 | 77 | 0.010 |
Why?
| | Drug Tolerance | 1 | 1993 | 79 | 0.010 |
Why?
| | Disease Progression | 1 | 1999 | 2418 | 0.010 |
Why?
| | Neutrophils | 2 | 1987 | 1172 | 0.010 |
Why?
| | Cell Cycle | 1 | 1994 | 546 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 1991 | 218 | 0.010 |
Why?
| | HLA-DP Antigens | 1 | 1991 | 32 | 0.010 |
Why?
| | Thromboxane A2 | 1 | 1990 | 12 | 0.010 |
Why?
| | Immunophenotyping | 1 | 1991 | 277 | 0.010 |
Why?
| | Histocompatibility Testing | 1 | 1990 | 115 | 0.010 |
Why?
| | Leukotriene B4 | 1 | 1990 | 48 | 0.010 |
Why?
| | Biological Assay | 1 | 1991 | 114 | 0.010 |
Why?
| | Antigen-Presenting Cells | 1 | 1990 | 153 | 0.010 |
Why?
| | Radioimmunoassay | 1 | 1990 | 163 | 0.010 |
Why?
| | Aspartate Aminotransferases | 1 | 1990 | 87 | 0.010 |
Why?
| | Alanine Transaminase | 1 | 1990 | 141 | 0.010 |
Why?
| | Alkaline Phosphatase | 1 | 1990 | 144 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 1992 | 383 | 0.010 |
Why?
| | Immunoglobulins | 1 | 1990 | 147 | 0.010 |
Why?
| | Epoprostenol | 1 | 1990 | 133 | 0.010 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 1992 | 221 | 0.010 |
Why?
| | Coroners and Medical Examiners | 1 | 1989 | 7 | 0.010 |
Why?
| | Virus Cultivation | 1 | 1989 | 25 | 0.010 |
Why?
| | Survival Rate | 1 | 1993 | 1650 | 0.000 |
Why?
| | Adrenal Cortex | 1 | 1988 | 32 | 0.000 |
Why?
| | Methods | 1 | 1988 | 58 | 0.000 |
Why?
| | Chemical Fractionation | 1 | 1988 | 28 | 0.000 |
Why?
| | Arterioles | 1 | 1988 | 40 | 0.000 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 1988 | 79 | 0.000 |
Why?
| | Metaraminol | 1 | 1987 | 1 | 0.000 |
Why?
| | Rats, Inbred WKY | 1 | 1987 | 32 | 0.000 |
Why?
| | Rats, Inbred SHR | 1 | 1987 | 41 | 0.000 |
Why?
| | Peroxidases | 1 | 1987 | 25 | 0.000 |
Why?
| | Mannitol | 1 | 1987 | 32 | 0.000 |
Why?
| | Adrenal Gland Neoplasms | 1 | 1988 | 81 | 0.000 |
Why?
| | Cell Membrane Permeability | 1 | 1987 | 83 | 0.000 |
Why?
| | Edetic Acid | 1 | 1987 | 44 | 0.000 |
Why?
| | Leukocyte Count | 1 | 1988 | 294 | 0.000 |
Why?
| | Propionibacterium | 1 | 1986 | 2 | 0.000 |
Why?
| | AIDS-Related Complex | 1 | 1986 | 3 | 0.000 |
Why?
| | HIV Antigens | 1 | 1987 | 17 | 0.000 |
Why?
| | Mitosis | 1 | 1988 | 164 | 0.000 |
Why?
| | Serum Albumin, Bovine | 1 | 1987 | 65 | 0.000 |
Why?
| | Blood-Brain Barrier | 1 | 1987 | 106 | 0.000 |
Why?
| | Carcinoma | 1 | 1988 | 200 | 0.000 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1986 | 47 | 0.000 |
Why?
| | Argon | 1 | 1986 | 20 | 0.000 |
Why?
| | Cell Division | 1 | 1988 | 759 | 0.000 |
Why?
| | Antigens, Viral | 1 | 1987 | 177 | 0.000 |
Why?
| | Agranulocytosis | 1 | 1986 | 31 | 0.000 |
Why?
| | Homosexuality | 1 | 1986 | 16 | 0.000 |
Why?
| | Regional Blood Flow | 1 | 1987 | 414 | 0.000 |
Why?
| | Hydrogen Peroxide | 1 | 1987 | 287 | 0.000 |
Why?
| | Light | 1 | 1988 | 337 | 0.000 |
Why?
| | Amino Acid Sequence | 1 | 1990 | 2000 | 0.000 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1985 | 34 | 0.000 |
Why?
| | Interleukin-1 | 1 | 1990 | 971 | 0.000 |
Why?
| | Biomarkers, Tumor | 1 | 1992 | 1048 | 0.000 |
Why?
| | Drug Synergism | 1 | 1986 | 317 | 0.000 |
Why?
| | Pilot Projects | 1 | 1990 | 1377 | 0.000 |
Why?
| | Brain Neoplasms | 1 | 1993 | 980 | 0.000 |
Why?
| | Tissue and Organ Procurement | 1 | 1989 | 243 | 0.000 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1986 | 166 | 0.000 |
Why?
| | Autoantigens | 1 | 1988 | 398 | 0.000 |
Why?
| | HLA-B27 Antigen | 1 | 1985 | 11 | 0.000 |
Why?
| | Anterior Eye Segment | 1 | 1985 | 9 | 0.000 |
Why?
| | Epithelial Cells | 1 | 1991 | 961 | 0.000 |
Why?
| | Molecular Sequence Data | 1 | 1990 | 2790 | 0.000 |
Why?
| | DNA | 1 | 1992 | 1356 | 0.000 |
Why?
| | Indians, North American | 1 | 1990 | 584 | 0.000 |
Why?
| | Hyperemia | 1 | 1985 | 44 | 0.000 |
Why?
| | Lymphokines | 1 | 1984 | 115 | 0.000 |
Why?
| | Structure-Activity Relationship | 1 | 1986 | 511 | 0.000 |
Why?
| | Gram-Negative Bacteria | 1 | 1985 | 67 | 0.000 |
Why?
| | Prevalence | 1 | 1990 | 2264 | 0.000 |
Why?
| | Ischemia | 1 | 1987 | 363 | 0.000 |
Why?
| | Hodgkin Disease | 1 | 1986 | 118 | 0.000 |
Why?
| | Monocytes | 1 | 1987 | 507 | 0.000 |
Why?
| | Cryptococcosis | 1 | 1984 | 23 | 0.000 |
Why?
| | Lymphatic Diseases | 1 | 1983 | 17 | 0.000 |
Why?
| | alpha 1-Antitrypsin | 1 | 1985 | 109 | 0.000 |
Why?
| | Clone Cells | 1 | 1984 | 248 | 0.000 |
Why?
| | Antibodies, Viral | 1 | 1986 | 527 | 0.000 |
Why?
| | Colitis | 1 | 1986 | 226 | 0.000 |
Why?
| | Pain | 1 | 1988 | 712 | 0.000 |
Why?
| | Meningitis | 1 | 1984 | 74 | 0.000 |
Why?
| | Kidney Transplantation | 1 | 1988 | 558 | 0.000 |
Why?
| | Microscopy, Fluorescence | 1 | 1984 | 402 | 0.000 |
Why?
| | Vasodilation | 1 | 1985 | 412 | 0.000 |
Why?
| | Biomechanical Phenomena | 1 | 1985 | 677 | 0.000 |
Why?
| | Endothelium, Vascular | 1 | 1988 | 845 | 0.000 |
Why?
| | Clinical Trials as Topic | 1 | 1986 | 941 | 0.000 |
Why?
| | Mice, Inbred BALB C | 1 | 1984 | 1168 | 0.000 |
Why?
| | Blood Pressure | 1 | 1987 | 1537 | 0.000 |
Why?
| | Pneumonia, Viral | 1 | 1986 | 344 | 0.000 |
Why?
| | Killer Cells, Natural | 1 | 1983 | 383 | 0.000 |
Why?
| | Sexual Behavior | 1 | 1984 | 440 | 0.000 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 1984 | 337 | 0.000 |
Why?
| | Lung | 1 | 1985 | 3672 | 0.000 |
Why?
|
|
Palestine's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|